Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Aspas Requena G.
- Gil C.
- Botella C.
- Aguiar E.
- Trigo F.
- Colorado M.
- del Bernal del Castillo T.
- Tormo M.
- Rodríguez Arbolí E.
- Serrano López J.
- García Boyero R.
- Castaño T.
- Herrera Puente P.
- Romero Riquelme M.A.
- Sayas Lloris M.J.
- Algarra-Algarra L.
- Rodriguez-Medina C.
- Sossa Melo C.L.
- Labrador Gomez J.
- Vives S.
- Salamero O.
- Amigo M.L.
- Valero Nuñez M.
- Rojas C.
- Bass F.
- García-Fortes M.
- Vidriales Vicente B.
- Polo M.
- Benavente C.
- Madrigal M.D.
- Espinoza M.
- Pérez-Encinas M.
- Amador Barciela M.L.
- Bautista G.
- Colmenares R.
- García-Ramírez P.
- Ibáñez Alis F.
- Barrios García M.
- Rodríguez-Macías G.
- López M.
- Oliva Hernández A.Y.
- Cerveró C.J.
- Bergua Burgues J.M.
Grupos
Abstract
In a large multicenter real-world cohort, we aimed to evaluate outcomes of FLAG-Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998–2024), including patients with primary refractory disease (36.9%) and first relapse episode (63.1%), with a median age of 52 years. Complete remission composite (CRc) was achieved 56.8%, including complete remission (CR) in 51.0%, CR with incomplete recovery in 4.0%, and morphological-free-state in 1.8%, enabling 35.2% of patients and 62% of responders to proceed to allogeneic transplantation without morphological disease. With median follow-up of 50.9 months, median overall survival (OS) was 10.2 months, with 5-year OS rate of 21.6%. Prior allogeneic transplantation (HR 0.54; p < 0.001) and relapse-free interval = 1 year (HR 0.75; p = 0.024) independently predicted improved OS, whereas modified high-risk cytogenetics including t(8; 21) (HR 3.58; p < 0.001), FLT3-ITD mutation at primary diagnosis (HR 1.61; p < 0.001), and age = 60 (HR 1.43; p < 0.001) conferred inferior OS. Validation of the SALFLAGE score demonstrated moderate discrimination (C-index 0.67), with 5-year survival of 38.4%, 27.2%, and 12.7% across risk categories (p < 0.001). Outcomes improved over periods (1998–2005 vs. 2006–2016 vs. 2017–2024): 30-day mortality was 6.9% vs. 9.3% vs. 5.0%, respectively (p = 0.030), and median OS was 7.8 versus 9.4 versus 11.1 months, respectively (p = 0.16). We confirm FLAG-Ida as a reference salvage regimen in fit R/R AML and validate the SALFLAGE score in this setting. © 2026 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.
Datos de la publicación
- ISSN/ISSNe:
- 0361-8609, 1096-8652
- Tipo:
- Article
- Páginas:
- 1692-1705
- DOI:
- 10.1002/ajh.70340
- PubMed:
- 42017547
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 2,600 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
AMERICAN JOURNAL OF HEMATOLOGY WILEY
Citas Recibidas en Web of Science: 1
Citas Recibidas en Scopus: 1
Documentos
- No hay documentos
Filiaciones
Keywords
- acute myeloid leukemia; FLAG-Ida; real-world; relapsed/refractory; salvage therapy
Portal de investigación